Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial

British Medical Journal

Volumn 323, Issue 7310, 2001, Pages 419-422

  Sundar, S ^a   Agrawal, G ^a   Rai, M ^a   Makharia, M K ^a   Murray, H W ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; ANTIPARASITIC AGENT; MILTEFOSINE; PAROMOMYCIN; PLACEBO;

ADOLESCENT; ADULT; ANTIPROTOZOAL ACTIVITY; ARTICLE; BACKACHE; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HUMAN; LEISHMANIA DONOVANI; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISCERAL LEISHMANIASIS; VOMITING;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; PILOT PROJECTS; RECURRENCE; TREATMENT OUTCOME;

EID: 0035949141     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Epidemiology of visceral leishmaniasis in India
2. Kala-azar cases and deaths
3. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic
4. Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches
5. Miltefosine: The long-awaited therapy for visceral leishmaniasis?
6. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
7. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: A study of 938 cases
8. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days
9. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony
10. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)
11. Treatment of visceral leishmaniasis in children with liposomal amphotericin B
12. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries
13. Low dose liposomal amphotericin B (AmBisome) in refractory Indian visceral leishmaniasis - A multicenter study
14. Ultra-short-course amphotericin B lipid complex treatment for antimony-unresponsive Indian visceral leishmaniasis
15. US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
16. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: A randomized dose-finding study